share_log

Double Medical Technology (SZSE:002901) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Double Medical Technology (SZSE:002901) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

双医疗科技 (SZSE:002901) 发布了健康的收益,但还有一些其他因素需要注意
Simply Wall St ·  11/07 08:18

Double Medical Technology Inc.'s (SZSE:002901) robust earnings report didn't manage to move the market for its stock. Our analysis suggests that shareholders have noticed something concerning in the numbers.

Double Medical Technology Inc.(SZSE:002901)强劲的收益报告未能推动其股票市场。 我们的分析表明,股东已经注意到数字中的一些令人关注的事情。

big
SZSE:002901 Earnings and Revenue History November 7th 2024
SZSE:002901盈利和营业收入历史 2024年11月7日

The Impact Of Unusual Items On Profit

除了稀释之外,还应该注意的是,万集科技在过去12个月中因不寻常项目获得了价值人民币3.5万元的利润。虽然我们希望看到利润增加,但当这些不寻常项目对利润做出重大贡献时,我们会更加谨慎。我们对全球大部分上市公司的数据进行了分析,发现不寻常项目往往是一次性的。这正如我们所期望的那样,因为这些提升被描述为"不寻常"。相对于其利润而言,万集科技在2021年12月前的不寻常项目贡献大。因此,我们可以推断出,这些不寻常项目正在使其财务利润显著增强。

For anyone who wants to understand Double Medical Technology's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥48m worth of unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. Which is hardly surprising, given the name. We can see that Double Medical Technology's positive unusual items were quite significant relative to its profit in the year to September 2024. As a result, we can surmise that the unusual items are making its statutory profit significantly stronger than it would otherwise be.

对于想要了解Double Medical Technology的利润超出法定数字的人来说,重要的是要注意,在过去十二个月中,法定利润中增加了价值4800万人民币的飞凡项目。 我们不能否认,更高的利润通常让我们感到乐观,但我们更希望利润能够持续。 当我们对数千家上市公司的数字进行分析时,我们发现,某一年份来自飞凡项目的增加往往不会在下一年重复。 这并不奇怪,考虑到名称。 我们可以看到,Double Medical Technology的积极飞凡项目与2024年9月之前的利润相比非常显著。 因此,我们可以推测,这些飞凡项目正在使其法定利润比其他情况下显著增强。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

这可能会让您想知道分析师对未来盈利能力的预测。幸运的是,您可以单击此处查看基于其估计的未来盈利能力的互动图表。

Our Take On Double Medical Technology's Profit Performance

我们对Double Medical Technology的盈利表现看法

As we discussed above, we think the significant positive unusual item makes Double Medical Technology's earnings a poor guide to its underlying profitability. For this reason, we think that Double Medical Technology's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. On the bright side, the company showed enough improvement to book a profit this year, after losing money last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. While conducting our analysis, we found that Double Medical Technology has 2 warning signs and it would be unwise to ignore them.

正如我们以上所讨论的,我们认为重要的正异常项目使得双倍医疗科技的收入成为其潜在盈利能力的糟糕指标。基于此原因,我们认为双倍医疗科技的法定利润可能是其潜在盈利能力的糟糕指标,并可能让投资者对公司有过于积极的印象。光明的一面是,该公司今年实现了足够的改进,盈利了,而去年还亏损。本文的目标是评估我们可以多大程度地依赖法定收益来反映公司的潜力,但还有很多要考虑。基于此,在进行更多关于该公司的分析时,了解涉及的风险是至关重要的。在进行分析时,我们发现双倍医疗科技存在2个警示信号,忽视它们是不明智的。

Today we've zoomed in on a single data point to better understand the nature of Double Medical Technology's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

今天我们聚焦一个单一数据点,以更好地了解双倍医疗科技利润的性质。但如果您能够专注于细节,总有更多可发现的。例如,许多人认为高股本回报率是有利的业务经济的指标,而其他人则喜欢‘跟踪资金’并寻找内部人员正在买入的股票。虽然这可能需要您进行一些研究,但您可能会发现这个免费收集的公司中的股票回报率高,或者具有重大内部持股的这份股票名单会很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发